

DAFTAR PUSTAKA

1. Emery AEH. The muscular dystrophies. *Lancet*. 2002;359:687–95.
2. Latimer R, Street N, Conway KC, James K, Cunliffe C, Oleszek J. Secondary conditions among males with Duchenne or Becker muscular dystrophy. *J Child Neurol*. 2017;32(7):663–70.
3. Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. *Eur J Heal Econ*. 2016;19–29.
4. Matthews E, Brassington R, Kuntzer T, Jichi F, Ay M. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review) Summary Of Findings For The Main Comparison. *Cochrane Database Syst Rev*. 2016;(5).
5. K F. Duchenne and Becker Muscular Dystrophies. In: Swaiman- KF, Ashwal S FD, editor. *Swaiman ' s Pediatric Neurology Principles and Practice Sixth Edition*. Elsevier; 2017. 1106–11 p.
6. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol*. 2010;9(1):77–93. Available from: [http://dx.doi.org/10.1016/S1474-4422\(09\)70271-6](http://dx.doi.org/10.1016/S1474-4422(09)70271-6)
7. Nicolas A, Raguènes-Nicol C, Yaou R Ben, Hir SA Le, Chéron A, Vié V, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. *Hum Mol Genet*. 2015;24(5):1267–79.
8. Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GKD, et al. Prevalence of duchenne and becker muscular dystrophies in the United States. *Pediatrics*. 2015;135(3):513–21.
9. Goldstein JA, McNally EM. Mechanisms of muscle weakness in muscular dystrophy. *J Gen Physiol*. 2010;136(1):29–34.
10. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment: Third in molecular medicine review series. *EMBO Rep*. 2004;5(9):872–6.
11. Kimura K, Morita H, Nakamura A, Takenaka K, Daimon M. Therapeutic Strategy for Heart Failure in Becker Muscular Dystrophy. *Int Heart J*. 2016;4–6.
12. Peverelli L, Testolin S, Villa L, D'Amico A, Petrini S, Favero C, et al. Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. *Neurology*. 2015;85(21):1886–93.
13. Suthar R, Sankhyani N. Duchenne Muscular Dystrophy: A Practice Update. *Indian J Pediatr*. 2018;85(4):276–81.
14. Hoffman EP, Fischbeck KH BR. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. *N Engl J Med*. 1988;318(21):1363–8.
15. Darras BT, Urien DK, Ghosh PS. Dystrophinopathies. *Dystrophinopathies Gene Rev*. 2018:1-21

16. Waldrop MA, Flanigan KM. Update in Duchenne and Becker muscular dystrophy. *Curr Opin Neurol*. 2019;32(5):722–7.
17. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. *J Neurol Neurosurg Psychiatry*. 2013;84(6):698–705.
18. Matthews DJ, James KA, Miller LA, Pandya S, Campbell KA, Ciafaloni E, et al. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. *J Child Neurol*. 2010;25(11):1319–24.
19. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. *J Paediatr Child Health*. 2015;51(8):759–64.
20. Johnsen S. Prednisone Therapy in Becker ' s Muscular. *J Child Neurol*. 2015;16(11):870–1.
21. Wein N, Alfano L, Flanigan KM. Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. *Pediatr Clin North Am*. 2015;62(3):723–42.
22. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy part 2: implementation of multidisciplinary care. *Lancet Neurol*. 2010;9(2):177–89. Available from: [http://dx.doi.org/10.1016/S1474-4422\(09\)70272-8](http://dx.doi.org/10.1016/S1474-4422(09)70272-8)
23. Al-Dahhak R, Kissel JT. Medical Management of Duchenne Muscular Dystrophy. In: Chamberlain J, Rando TA, editors. *Duchenne Muscular Dystrophy: Advances in Therapeutics*. New York: Taylor and Francis Inc.; 2006. p. 123–40.
24. Moxley R, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in Natural History of Duchenne Muscular Dystrophy With Long-term Corticosteroid Treatment : Implications for Management. *J Child Neurol*. 2010;000(00):1–14.
25. Simonds AK. Respiratory complications of the muscular dystrophies. *Semin Respir Crit Care Med*. 2002;23(3):231–8.
26. Uzark K, King E, Cripe L, Spicer R, Sage J, Kinnett K, et al. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. *Pediatrics*. 2012;130(6).
27. Young HK, Barton BA, Waisbren S, Dale LP, Ryan MM, Webster RI, et al. Cognitive and Psychological Profile of Males With Becker Muscular Dystrophy. *J Child Neurol*. 2008;23(2):155–62.
28. Hu J, Ye Y, Kong M, Hong S, Cheng L, Wang Q, et al. Daily prednisone treatment in duchenne muscular dystrophy in southwest china. *Muscle and Nerve*. 2015;52(6):1001–7.
29. Nakamura M, Sunagawa O, Hokama R, Tsuchiya H, Miyara T, Taba Y, et al. A case of refractory heart failure in becker muscular dystrophy improved with corticosteroid therapy. *Int Heart J*. 2016;57(5):640–4.
30. Hogrel JY, Ollivier G, Desnuelle C. Journées neuromusculaires Testing musculaire manuel et quantifié dans les maladies. *Rev Neurol*. 2006;162(4):427–36. [https://doi.org/10.1016/S0035-3787\(06\)75033-0](https://doi.org/10.1016/S0035-3787(06)75033-0)

31. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol.* 2018;17(4):347–61. Available from: [http://dx.doi.org/10.1016/S1474-4422\(18\)30025-5](http://dx.doi.org/10.1016/S1474-4422(18)30025-5)
32. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol.* 2018;17(3):251–67. Available from: [http://dx.doi.org/10.1016/S1474-4422\(18\)30024-3](http://dx.doi.org/10.1016/S1474-4422(18)30024-3)
33. Joshi S, Shrivastava S, Pandey C, Shrotriya P, Dixit A. Case report : Becker ' s muscular dystrophy. *Int J Med Heal Res.* 2017;3(7):94–6. Available from: <http://www.medicalsciencejournal.com/archives/2017/vol3/issue7>
34. Mavrogeni SI, Markousis-Mavrogenis G, Papavasiliou A, Papadopoulos G, Kolovou G. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. *Card Involv Duchenne Muscular Dystrophy Relat Dystrophinopathies.* 2018;1687(Xlcm):31.
35. Klitzner TS, Beekman RH, Galioto FM, Jones TK, Manning PB, Morrow WR, et al. Cardiovascular health supervision for individuals affected by duchenne or becker muscular dystrophy. *Pediatrics.* 2005;116(6):1569–73.
36. Buddhe S, Cripe L, Friedland-little J, Kertesz N, Eghtesady P, Finder J, et al. Cardiac management of the patient with Duchenne muscular dystrophy. *Pediatrics.* 2018;142:S99–106.
37. Poysky J. Behavior patterns in Duchenne muscular dystrophy: Report on the Parent Project Muscular Dystrophy behavior workshop 8-9 of December 2006, Philadelphia, USA. *Neuromuscul Disord.* 2007;17(11–12):986–94.
38. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *Lancet Neurol.* 2018;17(5):445–55. Available from: [http://dx.doi.org/10.1016/S1474-4422\(18\)30026-7](http://dx.doi.org/10.1016/S1474-4422(18)30026-7)
39. Mori-Yoshimura M, Mizuno Y, Yoshida S, Minami N, Yonemoto N, Takeuchi F, et al. Social involvement issues in patients with Becker muscular dystrophy: A questionnaire survey of subjects from a patient registry. *Brain Dev.* 2018;40(4):268–77. Available from: <https://doi.org/10.1016/j.braindev.2017.11.004>
40. Harahap DF, Sjarif DR, Widodo DP, Tedjasaputra MS. Identification of emotional and behavior problems in obese children using Child Behavior Checklist (CBCL) and 17-items Pediatric Symptom Checklist (PSC-17). *Paediatr Indones.* 2010;50(1):42–8.
41. Simonds AK. Respiratory Complications of the Muscular Dystrophies. 2002;22(3):231–8.
42. Topaloglu H. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.*

- 2016;87(2):238.
43. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma Clin Immunol.* 2013;9(1):1–25.
 44. Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, et al. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. *J Pediatr.* 2017;182:296–303.e1. Available from: <http://dx.doi.org/10.1016/j.jpeds.2016.11.078>
 45. Tosur M, Viau-Colindres J, Astudillo M, Redondo MJ, Lyons SK. Medication-induced hyperglycemia: Pediatric perspective. *BMJ Open Diabetes Res Care.* 2020;8(1):1–11.
 46. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. *Arch Dis Child.* 2016;0:1–6.
 47. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, José Gerardo González- González, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World J Diabetes* 2015. 2015;6(8):1073–81.
 48. Sekarwana N, Rachmadi D, Hilmanto D. Konsensus Tatalaksana Hipertensi pada Anak. IDAI. 2011;3–11.
 49. Alan IS, Alan B. Side Effects of Glucocorticoids. In: *Pharmacokinet Advers Eff Drugs - Mech Risks Factors.* Intech Open. 2018: 93–111 p.
 50. Söderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, et al. Bone mass development in patients with Duchenne and Becker muscular dystrophies: A 4-year clinical follow-up. *Acta Paediatr Int J Paediatr.* 2012;101(4):424–32.
 51. Buckner JL, Bowden SA, Mahan JD. Optimizing bone health in duchenne muscular dystrophy. *Int J Endocrinol.* 2015;2015.
 52. Perera N, Farrar M. Bone Health in Children with Duchenne Muscular Dystrophy: A Review. *Pediat Ther.* 2015;5(3):1–8.
 53. Bell JM, Shields MD, Watters J, Hamilton A, Beringer T, Elliott M, et al. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. *Cochrane Database Syst Rev.* 2017;2017(1).
 54. Mitra R. Adverse effects of corticosteroids on bone metabolism: A review. *American Academy of Physical Medicine and Rehabilitation.* 2011;3(5):466–71. Available from: <http://dx.doi.org/10.1016/j.pmrj.2011.02.017>
 55. Saure C, Caminiti C, Weglinski J, Castro F De, Monges S. Diabetes & Metabolic Syndrome : Clinical Research & Reviews Energy expenditure , body composition , and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy. *Diabetes Metab Syndr Clin Res Rev.* 2017;8–12. Available from: <http://dx.doi.org/10.1016/j.dsx.2017.08.006>
 56. Gedalia A, Shetty AK. Chronic Steroid and Immunosuppressant Therapy in Children. *Peds Rev.* 2019;25(12):425–33.

57. Dahlmann-Noor A, Tailor V, Bunce C, Abou-Rayyah Y, Adams G, Brookes J, et al. Quality of Life and Functional Vision in Children with Glaucoma. *Ophthalmology*. 2017;124(7):1048–55. Available from: <http://dx.doi.org/10.1016/j.ophtha.2017.02.024>
58. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. *PLoS One*. 2017;12(1):1–18.
59. Brumbaugh D, Watne L, Gottrand F, Gulyas A, Kaul A, Larson J, et al. Nutritional and gastrointestinal management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 2018;142:53–61.
60. Salera S, Menni F, Moggio M, Guez S, Sciacco M, Susanna Esposito. Nutritional Challenges in Duchenne Muscular Dystrophy. *Nutrients*. 2017;9(594):1–10.
61. Cruz Guzmán ODR, Chávez García AL, Rodríguez-Cruz M. Muscular dystrophies at different ages: Metabolic and endocrine alterations. *Int J Endocrinol*. 2012;2012:1-8.
62. Bello L, Campadello P, Barp A, Fanin M, Semplicini C, Sorarù G, et al. Functional changes in Becker muscular dystrophy: Implications for clinical trials in dystrophinopathies. *Sci Rep*. 2016;6:1–12. Available from: <http://dx.doi.org/10.1038/srep32439>
63. Hullmann SE, Ryan JL, Ramsey RR, Chaney JM, Mullins LL. Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL-R, Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales, and Quality of My Life Questionnaire (QoML). *Arthritis Care Res*. 2011;63(SUPPL. 11):420–30.
64. Sekartini R. Kualitas Hidup pada Anak dengan Penyakit Kronik. In: Partini P, Trihono, Prayitno A, Soebadi D, Amanda M, editors. *Pendekatan Holistik Penyakit Kronik Pada Anak untuk Meningkatkan Kualitas Hidup*. Pertama. Jakarta: Fakultas Kedokteran Indonesia Ilmu Kesehatan Anak; 2014. p. 147–53.
65. Finsterer J, Stöllberger C. Cardiac involvement in Becker muscular dystrophy. *Can J Cardiol*. 2008;24(10):786–92.
66. Wahab AS. *Elektrokardiografi Anak*. Yogyakarta: Bina Cipta; 1985. 62–70 p.
67. IDAI. *Pedoman Pelayanan Medis*. Pudjiadi AH, Hegar B, Handryastuti S, Gandaputra EP, Harmoniati ED, editors. Jakarta: Ikatan Dokter Anak Indonesia; 2009. 205–212 p.
68. Julia M, Utari A, Moelyo AG, Rochmah N. *Konsensus Nasional Pengelolaan Diabetes Melitus Tipe 2 Pada Anak dan Remaja*. Jakarta: UKK Endokrinologi Anak dan Remaja; 2015. p. 7–12.
69. Khoury M, Madsen N. Screening and Management of High Blood Pressure in Children and Adolescents. *JAMA Pediatr*. 2018;172(11):1087–8.
70. Flynn JT, Falkner BE. New clinical practice guideline for the management of high blood pressure in children and adolescents. *Hypertension*. 2017;70(4):683–6.
71. Rauch F, Plotkin H, DiMeglio L, Engelbert RH, Henderson RC, Munns C,

- et al. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD 2007 Pediatric Official Positions. *J Clin Densitom.* 2008;11(1):22–8.
72. Yoon JM. Dyslipidemia in children and adolescents: When and how to diagnose and treat? *Pediatr Gastroenterol Hepatol Nutr.* 2014;17(2):85–92.
73. De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. *Pediatrics.* 2011;128(SUPP.5):213–56.
74. Gedalia A, Shetty AK. Chronic steroid and immunosuppressant therapy in children. *Pediatr Rev.* 2004;25(12):425–34.
75. Iskandar K, Sunartini, Nugrahanto AP, Ilma N, Kalim AS, Adistyawan G, et al. Use of air stacking to improve pulmonary function in Indonesian Duchenne muscular dystrophy patients: Bridging the standard of care gap in low middle income country setting. *BMC Proc [Internet].* 2019;13(Suppl 11):1–7. Available from: <http://dx.doi.org/10.1186/s12919-019-0179-4>
76. Soos MP, McComb D. Sinus Arrhythmia. *StatPearls Publ.* 2020;
77. Kuroda K, Kato TS, Amano A. Hypertensive cardiomyopathy: A clinical approach and literature review. *World J Hypertens.* 2015;5(2):41.
78. Moxley RT, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: Corticosteroid treatment of Duchenne dystrophy - Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *American Academy of Neurology.* 2006;12(3):188–95.
79. UKK Nutrisi dan Penyakit metabolik. Diagnosis, Tata Laksana dan Pencegahan Obesitas pada Anak dan Remaja. *Ikat Dr Anak Indones.* 2014;1.
80. Al-Dahhak R, Kissel JT. Medical Management of Duchenne Muscular Dystrophy. In: Chamberlain JS, Rando TA, editors. *Duchennes Muscular Dystrophy : Advances in Theurapeutics.* New York: Taylor and Francis Inc.; 2006. p. 133.
81. Tsai M, Huang H, Chou Y, Cheng C, Chen J, Lin S. ScienceDirect Risk Factors for Hyperglycemia During Chemotherapy for Acute Lymphoblastic Leukemia Among Taiwanese Children. *Pediatr Neonatol.* 2015;56(5):339–45.
82. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. *J Am Acad Dermatol.* 2017;76(2):201–7. Available from: <http://dx.doi.org/10.1016/j.jaad.2016.02.1241>
83. Rice ML, Wong B, Horn PS, Yang MB. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients. *American Academy of Optometry.* 2018;22(3):192–6. Available from: <https://doi.org/10.1016/j.jaapos.2018.01.017>
84. Pradhan S, Ghosh D, Srivastava NK, Kumar A, Mittal B, Pandey CM, et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. *J Neurol.* 2006;253(10):1309–16.
85. Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. *J Fungi.*

- 2015;1(1):13–29.
86. Aartsma-Rus A, Dunnen JT den. Phenotype predictions for exon deletions/duplications: A user guide for professionals and clinicians using Becker and Duchenne muscular dystrophy as examples. *Hum Mutat.* 2019;1–4.
 87. Vengalil S, Preethish-Kumar V, Polavarapu K, Mahadevappa M, Sekar D, Purushottam M, et al. Duchenne muscular dystrophy and becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: Genotype-phenotype correlation in a large cohort. *J Clin Neurol.* 2017;13(1):91–7.